Jazz Pharmaceuticals Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Jazz Pharmaceuticals de 17.4% y 5.8% por año respectivamente. Se prevé que el BPA crezca en un 16% al año. Se espera que la rentabilidad financiera sea de 26.6% en 3 años.

Información clave

17.4%

Tasa de crecimiento de los beneficios

16.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	22.8%
Tasa de crecimiento de los ingresos	5.8%
Rentabilidad financiera futura	26.6%
Cobertura de analistas	Good
Última actualización	24 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off

Apr 15

Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price

Apr 02

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:JAZZ - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	4,605	726	1,654	1,485	17
12/31/2025	4,389	648	1,477	1,393	20
12/31/2024	4,095	475	1,299	1,159	20
12/31/2023	3,834	415	1,049	1,092	N/A
9/30/2023	3,794	80	867	1,267	N/A
6/30/2023	3,763	-87	987	1,377	N/A
3/31/2023	3,738	-156	918	1,384	N/A
12/31/2022	3,659	-224	774	1,272	N/A
9/30/2022	3,584	-19	984	1,108	N/A
6/30/2022	3,481	-52	809	964	N/A
3/31/2022	3,300	-450	622	702	N/A
12/31/2021	3,094	-330	733	779	N/A
9/30/2021	2,863	-161	711	787	N/A
6/30/2021	2,626	40	708	771	N/A
3/31/2021	2,436	518	750	912	N/A
12/31/2020	2,364	239	520	900	N/A
9/30/2020	2,280	179	455	801	N/A
6/30/2020	2,217	133	478	881	N/A
3/31/2020	2,188	280	509	847	N/A
12/31/2019	2,162	523	594	776	N/A
9/30/2019	2,056	609	726	907	N/A
6/30/2019	1,988	656	676	791	N/A
3/31/2019	1,954	486	646	834	N/A
12/31/2018	1,891	447	667	799	N/A
9/30/2018	1,851	520	642	785	N/A
6/30/2018	1,793	434	530	753	N/A
3/31/2018	1,687	447	578	696	N/A
12/31/2017	1,619	488	579	693	N/A
9/30/2017	1,579	372	N/A	669	N/A
6/30/2017	1,541	399	N/A	613	N/A
3/31/2017	1,528	408	N/A	605	N/A
12/31/2016	1,488	397	N/A	592	N/A
9/30/2016	1,432	363	N/A	531	N/A
6/30/2016	1,399	361	N/A	573	N/A
3/31/2016	1,352	335	N/A	587	N/A
12/31/2015	1,325	330	N/A	532	N/A
9/30/2015	1,312	328	N/A	545	N/A
6/30/2015	1,278	266	N/A	499	N/A
3/31/2015	1,235	222	N/A	434	N/A
12/31/2014	1,173	58	N/A	408	N/A
9/30/2014	1,081	32	N/A	353	N/A
6/30/2014	1,006	82	N/A	354	N/A
3/31/2014	923	80	N/A	287	N/A
12/31/2013	872	216	N/A	288	N/A
9/30/2013	820	327	N/A	314	N/A
6/30/2013	764	285	N/A	227	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (17.4% al año) de JAZZ es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que los beneficios (17.4% al año) de JAZZ crezcan más rápidamente que el mercado US (14.7% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de JAZZ crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (5.8% al año) de JAZZ crezcan más despacio que el mercado de US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 5.8% al año) de JAZZ crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de JAZZ sea alta dentro de 3 años (26.6%)

Jazz Pharmaceuticals Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates fall by 14%

Consensus EPS estimates fall by 41%

Jazz Pharmaceuticals plc Provides Earnings Guidance for the Full Year 2024

Jazz Pharmaceuticals plc Revises Earnings Guidance for the Year 2023

Jazz Pharmaceuticals plc Affirms Revenue Guidance for the Year 2023

Jazz Pharmaceuticals plc Raises Earnings Guidance for the Full Year 2022

Recent updates

Jazz Pharmaceuticals plc to Report Q1, 2024 Results on May 01, 2024

Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off

Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer

Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price

Executive VP & CFO recently bought US$1.4m worth of stock

Consensus EPS estimates fall by 14%

Consensus EPS estimates fall by 41%

New minor risk - Earnings quality

Full year 2023 earnings: EPS misses analyst expectations

Jazz Pharmaceuticals plc Provides Earnings Guidance for the Full Year 2024

Jazz Pharmaceuticals Announces Board Changes

Jazz Pharmaceuticals plc Appoints Philip Johnson as Executive Vice President, Effective March 1, 2024

Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?

Jazz Pharmaceuticals plc to Report Q4, 2023 Results on Feb 28, 2024

Updated View On Jazz Pharmaceuticals' 2025 Goals

Insufficient new directors

Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking

Kim Sablich to Departure as Executive Vice President and General Manager, US of Jazz Pharmaceuticals plc on December 31, 2023

Jazz Pharmaceuticals plc to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Annual Meeting

Third quarter 2023 earnings: EPS misses analyst expectations

Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Jazz Pharmaceuticals plc to Report Q3, 2023 Results on Nov 08, 2023

Jazz Pharmaceuticals plc Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xyw

Jazz Pharmaceuticals plc to Present Data from Trials of Bispecific Antibody Zanidatamab and Zepzelca

Jazz Pharmaceuticals plc Receives European Commission Approval for Enrylaze® for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Jazz Pharmaceuticals plc Announces Chief Financial Officer Changes, October 1, 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Jazz Pharmaceuticals plc Revises Earnings Guidance for the Year 2023

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in re Xyrem (Sodium Oxybate) Antitrust Litigation

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in In re Xyrem (Sodium Oxybate) Antitrust Litigation

Jazz Pharmaceuticals plc to Report Q2, 2023 Results on Aug 09, 2023

Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Jazz Pharmaceuticals plc, Annual General Meeting, Aug 03, 2023

Executive VP & Chief Legal Officer notifies of intention to sell stock

Jazz Pharmaceuticals plc and Zymeworks Inc. Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers

Jazz Pharmaceuticals plc Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023

Insider recently sold US$790k worth of stock

First quarter 2023 earnings: EPS misses analyst expectations

Jazz Pharmaceuticals plc Affirms Revenue Guidance for the Year 2023

We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt

Senior VP & Chief Accounting Officer notifies of intention to sell stock

Insider recently sold US$292k worth of stock

Insider notifies of intention to sell stock

Full year 2022 earnings: EPS misses analyst expectations

Jazz Pharmaceuticals plc to Report Q4, 2022 Results on Mar 01, 2023

Jazz Pharmaceuticals and Zymeworks Announces 84% Overall Survival At 18 Months from Phase 2 Trial Evaluating Zanidatamab in Her2-Expressing Metastatic Gastroesophageal Adenocarcinoma

Co-Founder notifies of intention to sell stock

Insider recently sold US$279k worth of stock

Independent Non-Executive Director recently sold US$65k worth of stock

Jazz Pharmaceuticals Presents New Findings From Caregiver Survey on Outcomes of Epidiolex® (cannabidiol) for Adult and Pediatric Patients With Severe, Childhood-Onset Epilepsies

Jazz Pharmaceuticals to Present Data Demonstrating Advancements in Epilepsy Outcomes At the 2022 American Epilepsy Society Annual Meeting

Independent Director recently sold US$1.0m worth of stock

Independent Director notifies of intention to sell stock

Executive VP & Chief Legal Officer recently sold US$500k worth of stock

Jazz Pharmaceuticals plc Announces U.S. FDA Approval of Monday/Wednesday/Friday Intramuscular Dosing Schedule for Rylaze® (Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn)

Third quarter 2022 earnings: EPS misses analyst expectations

Jazz Pharmaceuticals plc Raises Earnings Guidance for the Full Year 2022

Jazz Pharmaceuticals plc to Report Q3, 2022 Results on Nov 09, 2022

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Jazz Pharmaceuticals plc Reiterates Revenue Guidance for the Full Year 2022

Jazz Pharmaceuticals: Monopoly In The Narcolepsy Drug Market

Senior VP & Chief Accounting Officer exercised options and sold US$94k worth of stock

Jazz Pharmaceuticals Announces Initiation of Phase 3 Trial Evaluating Epidiolex Epidyolex (Cannabidiol) for Patients with Epilepsy with Myoclonic-Atonic Seizures

Jazz begins phase 3 trial of cannabis drug Epidiolex for rare epilepsy

Independent Director exercised options and sold US$805k worth of stock

Independent Director recently sold US$180k worth of stock

Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly